Cassava Sciences Inc

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cassava Sciences advances Phase III trial with strong financial footing

Cassava Sciences is progressing well with Phase III trial milestones and financial stability, poised to announce critical trial results by year-end.
While facing challenges in data accuracy and increased expenses, the company's proactive approach and strategic planning present significant growth opportunities.
By focusing on innovation and market transformation, Cassava Sciences is positioned to redefine Alzheimer's disease diagnosis and treatment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer’s disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

The stock price of ​Cassava Sciences, a clinical stage biotechnology company focused on treatment for Alzheimer's disease, has seen a massive 66% rise over the last twenty-one trading days, while it is up a whopping 10x year-to-date, rising from levels of around $7 at the beginning of the year to.

Will The Rally In Cassava Sciences Stock Continue After A Large 66% Rise In A Month?

Selection of Premier Research as CRO Marks Significant Milestone Toward Initiation of Phase 3 Program of Simufilam in Alzheimer's Disease Selection of Premier Research as CRO Marks Significant Milestone Toward Initiation of Phase 3 Program of Simufilam in Alzheimer's Disease

Cassava Sciences Selects Clinical Research Organization for Phase 3 Clinical Program in Alzheimer's Disease

Cassava Sciences Inc (NASDAQ:SAVA) shares are trading higher by 11.2% at $88.50 after the company highlighted clinical development progress and provided guidance on upcoming data releases for simufilam, the company's lead drug candidate to treat Alzheimer's disease. Cassava Sciences is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease.

Why Cassava Sciences Shares Are Moving Today

Cassava Sciences Inc (NASDAQ: SAVA) has announced a mid-year update highlighting clinical development progress and providing guidance on upcoming data releases for simufilam and SavaDx.  Simufilam is Cassava's lead drug candidate to treat Alzheimer's disease; SavaDx is an investigational diagnostic candidate to detect Alzheimer's with a simple blood test.

Cassava Sciences Stock Gains After Outlining Clinical Development Progress For Lead Alzheimer's Candidate

AUSTIN, Texas, June 21, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer's disease, today announced a mid-year update that highlights clinical development progress and provides guidance on upcoming data releases for simufilam and SavaDx. Simufilam is Cassava Sciences' lead drug candidate to treat Alzheimer's disease; SavaDx is an investigational diagnostic candidate to detect Alzheimer's with a simple blood test.

Cassava Sciences Provides Mid-Year Corporate Update, Clinical Development Progress and Announces Guidance on Clinical Data Release

AUSTIN, Texas, June 17, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced that it has been invited to present at the Raymond James 2021 Human Health Innovation Conference, a virtual event taking place on June 21-23, 2021.

Cassava Sciences to Present at the Raymond James 2021 Human Health Innovation Conference

Annovis Bio

New approaches to treating Alzheimer's could mean even bigger gains in the future.

These 2 Biotech Stocks Are Up 1,000% This Year

- Mr. Barry To Contribute Additional Board-level Perspective Around Growth, Governance, Sustainability and Societal Goals –

Cassava Sciences Announces the Appointment of Richard J. Barry to its Board of Directors

Data doesn't lie. These companies have the potential to quickly steal the spotlight.

Ignore Biogen: 3 Reasons These Stocks Will Be Better Alzheimer's Investments

Arvinas Inc

Anavex Life Sciences

Virtus LifeSci Biotech Clinical Trials ETF

VanEck Vectors Biotech ETF

Virtus LifeSci Biotech Products ETF

Biohaven Pharmaceutical Hld

Biogen

Loncar Cancer Immunotherapy ETF

Denali Therapeutics

First Trust NYSE Arca Biotechnology Index Fund

Amplify Treatments Testing & Advancements ETF

Global X Genomics & Biotechnology ETF

abrdn Life Sciences Investors 

iShares Nasdaq Biotechnology ETF

Defiance Nasdaq Junior Biotechnology ETF

INmune Bio Inc

Intra-Cellular Therapies

Karuna Therapeutics Inc

Direxion Daily S&P Biotech Bear 3X Shares

Direxion Daily S&P Biotech Bull 3X Shares

Eli Lilly

Invesco Dynamic Biotechnology & Genome ETF

Prothena

Supernus Pharmaceuticals

SPDR S&P Biotech ETF

Health Care Select Sector SPDR Fund

Biotechs are ready to march forcefully higher after a lengthy consolidation. Approval of Biogen's Alzheimer's treatment creates a bonanza for neurodegenerative-focused companies and the overall biotech sector.

Biotechs Ready To Roar

FDA approves Biogen's (BIIB) Alzheimer's disease ("AD") drug, Aduhelm (aducanumab). Stocks of Eli Lilly (LLY), Cassava Sciences (SAVA) and Annovis Bio (ANVS) rise as they also have AD candidates in their portfolio.

3 Drug Stocks Rise as FDA Okays Biogen Alzheimer's Drug

Thanks to key funding, its Alzheimer's drug is on track even after Biogen's historic approval.

Why Cassava Sciences Was Up 15% in May

There are better options for investors looking to profit from potential Alzheimer's disease treatments.

Forget Biogen: These 2 Alzheimer's Drug Stocks Could Make You Rich

Avadel Pharma

Neurocrine Biosciences

SAGE Therapeutics

Healthcare faces an important decision as the Supreme Court decides on the Affordable Care Act. Biotechs face an important FDA decision on approval of an Alzheimer's treatment.

Healthcare And Biotech Stocks Face Important Decisions, Remain A Promising Investment

Investors need to pay close attention to Cassava Sciences (SAVA) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Cassava Sciences (SAVA) Stock?

Annovis Bio tripled Friday after reporting exciting Alzheimer's data. Its drug posiphen is not clearing plaques or flooding receptors, but inhibits amyloid-β precursor protein from translating toxic Aβ.

Annovis' Alzheimer's Drug Is Interesting, Cassava's Looks Better

- Virtual Panel to be Held on Wednesday, May 26 th , 11:00am Eastern Time -

Cassava Sciences to Participate in Q&A Panel Discussion on Alzheimer's Disease

The only effective Alzheimer's treatment on the market is aricept, but its effect falls off after six months because it simply floods receptors.

Long-Term Small Molecule Studies Bode Well For Cassava Sciences' Alzheimer's Data

Caladrius Biosciences

Caladrius Biosciences Inc (NASDAQ: CLBS) has received $1.4 million in non-dilutive funding as an approved participant of the Technology Business Tax Certificate Transfer Program sponsored by the New Jersey Economic Development Authority. The Program enables qualifying companies to sell a percentage of their New Jersey net operating losses and research and development tax credits to unrelated qualifying corporations.

Caladrius Biosciences, Cassava Sciences Secure Non-Dilutive Funding For Product Development

- Research Grant Will Support Clinical Readiness Activities in Support of Upcoming Phase 3 Program with Simufilam - - Research Grant Will Support Clinical Readiness Activities in Support of Upcoming Phase 3 Program with Simufilam -

Cassava Sciences Announces New $2.7 Million Research Grant Award from National Institutes of Health

The stock is off >70% from February high after going up 3x after the interim Alzheimer's data. Targeting $70 by the second interim data release in July (70% upside potential).

Buying Cassava Sciences Ahead Of July Data

- Randomized, Controlled Study is Designed to Evaluate Cognition  in Patients Who Continue Versus Discontinue Simufilam Over Six Months –

Cassava Sciences Announces Initiation of Cognition Maintenance Study in Alzheimer's disease

The shares of Cassava Sciences Inc (NASDAQ: SAVA) have received a price target of $78 by B. Riley. These are the details.

SAVA Stock: $78 Target By B. Riley

AUSTIN, Texas, April 26, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, today announced that it has been invited to participate in the Sachs 4th Annual Neuroscience Innovation Forum, a virtual event held on April 28-30, 2021. The National Institute on Aging of the National Institutes of Health (NIH) has invited Cassava Sciences to showcase its scientific program at this event.

Cassava Sciences Invited by the NIH to Participate in Sachs 4th Annual Neuroscience Innovation Forum

Axsome Therapeutics

Jazz Pharmaceuticals

While Biogen rides a big-cap rollercoaster, a few small players are creating better trading opps.

Alzheimer's Disease: 5 Stocks on Biotech Radars

News for Cassava Sciences Inc Stock (SAVA)